You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Details for New Drug Application (NDA): 008578


✉ Email this page to a colleague

« Back to Dashboard


NDA 008578 describes DARAPRIM, which is a drug marketed by Tilde Sciences and is included in one NDA. It is available from three suppliers. Additional details are available on the DARAPRIM profile page.

The generic ingredient in DARAPRIM is pyrimethamine. There are three drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the pyrimethamine profile page.
Summary for 008578
Tradename:DARAPRIM
Applicant:Tilde Sciences
Ingredient:pyrimethamine
Patents:0
Pharmacology for NDA: 008578
Medical Subject Heading (MeSH) Categories for 008578
Suppliers and Packaging for NDA: 008578
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DARAPRIM pyrimethamine TABLET;ORAL 008578 NDA Vyera Pharmaceuticals LLC 69413-330 69413-330-10 100 TABLET in 1 BOTTLE, PLASTIC (69413-330-10)
DARAPRIM pyrimethamine TABLET;ORAL 008578 NDA Vyera Pharmaceuticals LLC 69413-330 69413-330-30 30 TABLET in 1 BOTTLE, PLASTIC (69413-330-30)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.